Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of “Hold” by Brokerages


Share on StockTwits

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has been assigned a consensus recommendation of “Hold” from the six research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $53.00.

A number of equities analysts have issued reports on PHAT shares. Jonestrading initiated coverage on shares of Phathom Pharmaceuticals in a research report on Thursday, January 28th. They set a “buy” rating for the company. Guggenheim initiated coverage on shares of Phathom Pharmaceuticals in a research report on Tuesday, February 2nd. They set a “buy” rating and a $60.00 target price for the company. Needham & Company LLC upped their price target on shares of Phathom Pharmaceuticals from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, December 15th. Zacks Investment Research lowered Phathom Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 3rd. Finally, BMO Capital Markets assumed coverage on Phathom Pharmaceuticals in a research note on Wednesday, February 17th. They issued an “outperform” rating and a $63.00 target price on the stock.

In other news, COO Azmi Nabulsi sold 14,500 shares of the stock in a transaction that occurred on Tuesday, February 2nd. The stock was sold at an average price of $39.89, for a total transaction of $578,405.00. Also, Director David A. Socks sold 55,000 shares of Phathom Pharmaceuticals stock in a transaction on Friday, March 12th. The shares were sold at an average price of $47.58, for a total transaction of $2,616,900.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,926 shares of company stock valued at $9,345,504. Insiders own 39.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Phathom Pharmaceuticals during the 4th quarter worth about $10,941,000. JPMorgan Chase & Co. increased its stake in Phathom Pharmaceuticals by 15.0% during the 4th quarter. JPMorgan Chase & Co. now owns 187,006 shares of the company’s stock worth $6,212,000 after buying an additional 24,411 shares in the last quarter. Luminus Management LLC purchased a new stake in Phathom Pharmaceuticals during the 4th quarter worth approximately $4,216,000. Squarepoint Ops LLC acquired a new position in shares of Phathom Pharmaceuticals during the fourth quarter valued at approximately $949,000. Finally, Pura Vida Investments LLC purchased a new position in shares of Phathom Pharmaceuticals in the fourth quarter valued at approximately $1,993,000. 73.80% of the stock is owned by institutional investors and hedge funds.

Shares of PHAT opened at $38.73 on Thursday. The firm has a market capitalization of $1.21 billion, a PE ratio of -2.77 and a beta of 1.32. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.21 and a quick ratio of 8.21. The company’s fifty day moving average price is $43.29 and its 200-day moving average price is $40.62. Phathom Pharmaceuticals has a 1-year low of $27.47 and a 1-year high of $64.54.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings data on Monday, March 29th. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.57). As a group, research analysts anticipate that Phathom Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Featured Article: Find a Trading Strategy That Works

Analyst Recommendations for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.